CAR-NK cells: A promising cellular immunotherapy for cancer
Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can
kill target cells through similar cytotoxic mechanisms. With the remarkable success of …
kill target cells through similar cytotoxic mechanisms. With the remarkable success of …
Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
RL Barrett, E Puré - Elife, 2020 - elifesciences.org
Fibroblasts play an essential role in organogenesis and the integrity of tissue architecture
and function. Growth in most solid tumors is dependent upon remodeling 'stroma', composed …
and function. Growth in most solid tumors is dependent upon remodeling 'stroma', composed …
Immunometabolism and natural killer cell responses
KL O'Brien, DK Finlay - Nature Reviews Immunology, 2019 - nature.com
Natural killer (NK) cells are lymphocytes with important roles in innate and adaptive immune
responses to tumours and viral infection. However, in certain chronic diseases, including …
responses to tumours and viral infection. However, in certain chronic diseases, including …
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
H Zhu, RH Blum, R Bjordahl… - Blood, The Journal …, 2020 - ashpublications.org
Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of natural killer
(NK) cells that is mediated by therapeutic monoclonal antibodies (mAbs). This process is …
(NK) cells that is mediated by therapeutic monoclonal antibodies (mAbs). This process is …
Emerging targeted therapies for HER2-positive breast cancer
MF Mercogliano, S Bruni, FL Mauro, R Schillaci - Cancers, 2023 - mdpi.com
Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …
of the more aggressive and has the worst overall survival rate among them. These patients …
From CAR-T cells to CAR-NK cells: a developing immunotherapy method for hematological malignancies
H Lu, X Zhao, Z Li, Y Hu, H Wang - Frontiers in Oncology, 2021 - frontiersin.org
The approval of CD19 chimeric antigen receptor (CAR)-engineered T (CAR-T) cell products
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …
in B-cell malignancies represents a breakthrough in CAR-T cell immunotherapy. However …
Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma
D Martínez Bedoya, V Dutoit, D Migliorini - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
Chimeric antigen receptor-and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
C Zhang, Y Hu, W Xiao, Z Tian - Cellular & Molecular Immunology, 2021 - nature.com
Chimeric antigen receptor (CAR)-engineered T-cell (CAR-T) therapy has demonstrated
impressive therapeutic efficacy against hematological malignancies, but multiple challenges …
impressive therapeutic efficacy against hematological malignancies, but multiple challenges …
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity
Chimeric antigen receptor (CAR) T cells are a rapidly emerging form of cancer treatment,
and have resulted in remarkable responses in refractory lymphoid malignancies. However …
and have resulted in remarkable responses in refractory lymphoid malignancies. However …
Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects
Natural Killer (NK) cells are critical members of the innate immunity lymphocytes and have a
critical role in host defense against malignant cells. Adoptive cell therapy (ACT) using …
critical role in host defense against malignant cells. Adoptive cell therapy (ACT) using …